Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis

Modern Pathology

Volumn 24, Issue 6, 2011, Pages 846-854

  Espinosa, Inigo ^a   Catasus, Lluis ^a   Canet, Belén ^a   D'Angelo, Emanuela ^a   Mũoz, Josefina ^a   Prat, Jaime ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

clustering analysis; high grade serous carcinomas; outcome; PI3K AKT pathway

Indexed keywords

CASPASE 3; FAS ANTIGEN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER GRADING; CLEAR CELL CARCINOMA; CLUSTER ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MACROPHAGE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CASPASE 3; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 79957916562     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.12     Document Type: Article

References (44)

1. Scully R, Young R, Clement P. Tumors of the ovary, maldevelopment gonads, fallopian tube, and broad ligaments. Armed Forces Institute of Pathology: Washington, DC, 1998.
2. Prat J. Pathology of the ovary. Saunders: Philadelphia, 2004.
3. du Bois A, Luck HJ, Meier W, et al A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
4. International Collaborative Ovarian Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360: 505-515.
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
6. Cully M, You H, Levine AJ, et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-192. (Pubitemid 43292562)
7. Catasus L, D'Angelo E, Pons C, et al Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade en-dometrial carcinomas with different molecular alterations. Mod Pathol 2010;23:694-702.
8. Catasus L, Gallardo A, Cuatrecasas M, et al Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009;22:522-529.
9. Maffucci T, Piccolo E, Cumashi A, et al Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res 2005;65:8339-8349. (Pubitemid 41330599)
10. Levine DA, Bogomolniy F, Yee CJ, et al Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-2878. (Pubitemid 40525186)
11. Hu L, Hofmann J, Lu Y, et al Inhibition of phospha-tidylinositol 3-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087-1092. (Pubitemid 34160292)
12. Altomare DA, Wang HQ, Skele KL, et al AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004;23:5853-5857. (Pubitemid 39093031)
13. Opel D, Poremba C, Simon T, et al Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007;67:735-745. (Pubitemid 46192214)
14. Bader AG, Kang S, Zhao L, et al Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-929. (Pubitemid 41766781)
15. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999;6:99-104. (Pubitemid 29082297)
16. Silke J, Hawkins CJ, Ekert PG, et al The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3-and caspase 9-interacting sites. J Cell Biol 2002;157:115-124. (Pubitemid 34847834)
17. Hashiguchi Y, Tsuda H, Inoue T, et al PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 2006;101:71-75.
18. Roh MH, Yassin Y, Miron A, et al High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 2010;23:1316-1324.
19. Kuo KT, Mao TL, Chen X, et al DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010;16:1997-2008.
20. Schraml P, Schwerdtfeger G, Burkhalter F, et al Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003;163:985-992. (Pubitemid 37040134)
21. Canet B, Pons C, Espinosa I, et al Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior. Hum Pathol 3 January 2011 (e-pub ahead of print).
22. Devi GR. XIAP as target for therapeutic apoptosis in prostate cancer. Drug News Perspect 2004;17:127-134. (Pubitemid 38568410)
23. Sasaki H, Sheng Y, Kotsuji F, et al Down-regulation of X-linked inhibitor of apoptosis protein induces apop-tosis in chemoresistant human ovarian cancer cells. Cancer Res 2000;60:5659-5666.
24. Ma JJ, Chen BL, Xin XY. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 2009;146:222-226.
25. Arafa el SA, Zhu Q, Barakat BM, et al Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res 2009; 69: 8910-8917.
26. Lee Y, Medeiros F, Kindelberger D, et al Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 2006;13:1-7. (Pubitemid 44357143)
27. Medeiros F, Muto MG, Lee Y, et al The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-236. (Pubitemid 43740193)
28. Kindelberger DW, Lee Y, Miron A, et al Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161-169. (Pubitemid 46175016)
29. Piek JM, van Diest PJ, Zweemer RP, et al Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-456. (Pubitemid 33069670)
30. Colgan TJ, Murphy J, Cole DE, et al Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-1289. (Pubitemid 32917122)
31. Lee Y, Miron A, Drapkin R, et al A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35. (Pubitemid 46092026)
32. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518. (Pubitemid 38529752)
33. Yang XH, Sladek TL, Liu X, et al Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin-and etoposide-induced apoptosis. Cancer Res 2001;61:348-354. (Pubitemid 32095737)
34. Devarajan E, Sahin AA, Chen JS, et al Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002;21:8843-8851. (Pubitemid 36132404)
35. Materna V, Surowiak P, Markwitz E, et al Expression of factors involved in regulation of DNA mismatch repair-and apoptosis pathways in ovarian cancer patients. Oncol Rep 2007;17:505-516.
36. Kleinberg L, Dong HP, Holth A, et al Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol 2009;40:795-806.
37. West RB, van de Rijn M. Experimental approaches to the study of cancer-stroma interactions: recent findings suggest a pivotal role for stroma in carcinogenesis. Lab Invest 2007;87:967-970. (Pubitemid 47429192)
38. Milliken D, Scotton C, Raju S, et al Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002;8: 1108-1114. (Pubitemid 35177363)
39. Tothill RW, Tinker AV, George J, et al Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-5208.
40. Zhang L, Conejo-Garcia JR, Katsaros D, et al Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348: 203-213. (Pubitemid 36077915)
41. Sato E, Olson SH, Ahn J, et al Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-18543. (Pubitemid 43011261)
42. Conze D, Weiss L, Regen PS, et al Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001;61: 8851-8858. (Pubitemid 34013900)
43. Penson RT, Kronish K, Duan Z, et al Cytokines IL-1 beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000;10:33-41. (Pubitemid 30219476)
44. Wang Y, Niu XL, Qu Y, et al Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010;295: 110-123.